4AK-23571-01735
4 vaccinations
3 coded responses
40 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 432 / OH
- Registered
- 2021-01-11
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-11
Registered in v-safe
-
2021-01-12
Dose 1 — Moderna
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-21
- 2021-01-26
- 2021-02-02
-
2021-02-09
Dose 2 — Moderna
- 2021-02-09
-
2021-02-10
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Headache, Joint pains, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-02-11
- 2021-02-12
- 2021-02-13
- 2021-02-14
- 2021-02-15
- 2021-02-16
- 2021-02-23
- 2021-03-02
- 2021-03-09
- 2021-03-16
- 2021-03-23
- 2021-05-11
- 2021-08-10
-
2021-11-23
Dose 3 — Pfizer-BioNTech
-
2021-11-24
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, DiarrheaAdult check-in
- 2021-11-25
- 2021-11-26
- 2021-11-27
- 2021-11-28
- 2021-11-29
- 2021-11-30
- 2021-12-07
- 2021-12-16
- 2021-12-21
- 2021-12-28
-
2022-01-04
Survey response — day 42, dose 3MedDRA: Menstruation delayed — Feeling: GoodFree text: Delayed menstrual periodMedDRA releases: 2024-11 · check-in free text available
-
2022-02-22
Survey response — 3 months, dose 3MedDRA: Palpitations — Feeling: GoodFree text: Heart palpitationsMedDRA releases: 2024-11 · check-in free text available
- 2022-05-24
-
2022-09-23
Dose 4 — Moderna
-
2022-11-23
Survey response — 12 months, dose 3MedDRA: Urticaria — Feeling: Fair · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Spontaneous urticaria for 3+ weeks with onset approximately one month following the bivalent booster (Moderna)MedDRA releases: 2024-11 · check-in free text available
-
2022-11-23
Report sent to call center — 12 months, dose 3Be unable to work or attend school · Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-11-25
- 2022-12-25
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-12 | Moderna | |
| 2 | 2021-02-09 | Moderna | |
| 3 | 2021-11-23 | Pfizer-BioNTech | No |
| 4 | 2022-09-23 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-11-23 | Unsuccessful |
Free text
Release 10 — day 42, dose 3
Symptoms: Delayed menstrual period
Release 11 — 3 months, dose 3
Symptoms: Heart palpitations
Release 12 — 12 months, dose 3
Symptoms: Spontaneous urticaria for 3+ weeks with onset approximately one month following the bivalent booster (Moderna)
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Menstruation delayed | · | · | ✓ |
| SD | Palpitations | · | · | ✓ |
| SD | Urticaria | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release